You are here: Industry Insights > Paratek

News List

Paratek Pharmaceuticals Announces FDA Orphan Drug Designation for NUZYRA (omadacycline) for the Treatment of Infections Caused by Nontuberculous Mycobacteria firstwordpharma
August 19, 2021
Paratek Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation for NUZYRA® (omadacycline) for the treatment of infections
Paratek Announces FDA Approval of NUZYRA® for Treatment of Community-Acquired Bacterial Pneumonia americanpharmaceuticalreview
June 04, 2021
Paratek Pharmaceuticals Inc. announced that the U.S. FDA has approved the Company’s supplemental New Drug Application (sNDA) for the oral-only dosing regimen of NUZYRA® for the treatment of adults with Community-Acquired Bacterial Pneumonia (CABP).
Green light for acne drug Seysara in the US pharmatimes
October 11, 2018
US regulators have approved Paratek’s Seysara for the treatment of acne in patients aged nine years or older.
EU accepts marketing application for Paratek’s antibiotic pharmatimes
October 11, 2018
European regulators have accepted an application from Paratek Pharmaceuticals seeking approval of the broad-spectrum antibiotic omadacycline for two types of infection.
Paratek rising fast after Bloomberg says it is up for sale fiercebiotech
August 24, 2017
CEO Michael Bigham has said omadacycline has blockbuster potential.
Paratek Pharmaceuticals Opens New Office in King of Prussia, PA americanpharmaceuticalreview
March 27, 2017
Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, has opened its expanded office in King of Prussia, Pennsylvania.